Oncogenes in myeloproliferative disorders.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative disorders (MPDs) are a group of blood cancers involving the overproduction of myeloid cells.
• First described by William Dameshek in 1951, MPDs encompass conditions like chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
• The list of MPDs has expanded to include chronic neutrophilic leukemia (CNL), eosinophilic leukemia (CEL), myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), hypereosinophilic syndrome (HES), and systemic mastocytosis (SM).

Purpose of the Study:

• To review the classification and molecular underpinnings of myeloproliferative disorders (MPDs).
• To highlight the role of acquired somatic mutations in the pathogenesis of MPDs.
• To emphasize the impact of identifying these mutations on translational research and targeted drug development.

Main Methods:

• Review of historical classification and current understanding of MPDs.
• Identification and categorization of key somatic mutations associated with specific MPDs.
• Analysis of the link between molecular mutations and disease characteristics.

Main Results:

• MPDs are stem cell-derived clonal proliferative diseases driven by dysregulated signal transduction.
• Key mutations include BCR-ABL in CML, JAK2V617F in PV/ET/PMF, JAK2 exon 12 in PV, MPLW515L/K in PMF/ET, KITD816V in SM, and others.
• The discovery of these mutations has significantly advanced molecularly targeted drug development for MPDs.

Conclusions:

• MPDs share common features of myeloid lineage overproliferation due to acquired somatic mutations.
• Specific mutations are strongly associated with distinct MPD subtypes, aiding in diagnosis and classification.
• The growing list of identified mutations is crucial for advancing targeted therapies and improving patient outcomes in MPDs.